Related Experiment Video
Updated: Sep 9, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
[Therapeutic effect of defibrase in chronic glomerulonephritis with chronic renal failure]
Insights
Defibrase, derived from viper venom, improved kidney function in chronic renal failure patients by reducing fibrin deposition and thromboembolic lesions. This treatment alleviated uremia symptoms and improved renal parameters.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Context:
- Chronic glomerulonephritis (CGN) progressing to chronic renal failure (CRF) is characterized by decreased fibrinolysis and glomerular fibrin deposition, leading to thromboembolic lesions.
- This study investigates a novel therapeutic approach for CGN patients with CRF.
Purpose:
- To evaluate the efficacy and safety of defibrase, a fibrinolytic agent derived from viper venom, in treating chronic renal failure (CRF) secondary to chronic glomerulonephritis (CGN).
Summary:
- 46 CGN patients with CRF received defibrase (0.025 units/kg) infusions every 3 days for 6 treatments.
- Post-treatment, patients showed reduced Blood Urea Nitrogen (BUN) and serum creatinine, improved creatinine clearance, and alleviation of uremic symptoms.
- Hemoglobin levels increased, urinary protein excretion decreased, and hypertension was controlled in most patients when combined with captopril. Increased urinary output correlated with therapeutic effect.
Impact:
- Defibrase therapy may improve renal function in CGN patients with CRF by resolving glomerular fibrin deposition and thromboembolic lesions.
- The study suggests potential benefits in managing uremia and associated complications, although careful dose determination is needed due to bleeding risks.
Abstract:
When chronic glomerulonephritis (CGN) proceeds to chronic renal failure (CRF), there are decline of fibrinolytic activity and deposition of fibrin in glomeruli with resulting thromboembolic lesions. 46 CGN patients with complicating CRF were thus treated with defibrase made from viper venom. Defibrase in a dose of 0.025 unit/kg dissolved in 250 ml 10% glucose was infused slowly once every 3 days in a total of 6 times. After the treatment, BUN and serum creatinine levels decreased, creatinine cleance improved and the clinical manifestations of uremia alleviated or disappeared. In some patients there were increase of hemoglobin concentration and decrease of urinary protein excretion. Hypertension was controlled in 17 out of 20 patients treated in combination with captopril. Level of plasma fibrinogen was significantly reduced after defibrase administration, but the reduction was not related to the therapeutic effect. Urinary output was increased in most of the patients, being related to the therapeutic effect. The authors are of the opinion that renal function may be improved in CGN patients after defibrase treatment due probably to elimination of fibrin deposition and resolution of thromboembolic lesions in glomeruli. However, a suitable dose has to be determined as there is no effective way to monitor the most dreaded complication of defibrase therapy bleeding.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

